Company Description
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide.
The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents.
The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.
| Country | United States |
| Founded | 1976 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 179 |
| CEO | Ms. Kara Cannon |
Contact Details
Address: 60 Executive Blvd Farmingdale, New York 11735 United States | |
| Phone | (516) 755-5500 |
| Website | enzo.com |
Stock Details
| Ticker Symbol | ENZ |
| Exchange | NYSE |
| Fiscal Year | August - July |
| Reporting Currency | USD |
| CIK Code | 0000316253 |
| CUSIP Number | 294100102 |
| ISIN Number | US2941001024 |
| Employer ID | 13-2866202 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Kara Cannon | Chief Executive Officer |
| Patricia Eckert CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 10-Q | Quarterly Report |
| Feb 27, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2024 | 8-K | Current Report |
| Dec 21, 2023 | DEFR14A | Filing |
| Dec 21, 2023 | ARS | Filing |
| Dec 15, 2023 | 10-Q | Quarterly Report |
| Nov 28, 2023 | 10-K/A | [Amend] Annual report |